तुलना करने के लिए मीट्रिक्स | IVX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIVXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.6x | −5.4x | −0.5x | |
PEG अनुपात | 0.02 | 0.01 | 0.00 | |
क़ीमत/बुक | 1.1x | 3.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 11.7x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 75.1% | 50.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 23.8% | 7.7% | अनलॉक करें |
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.